Trial Profile
Long-term Experience With Abatacept SC in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASCORE
- Sponsors Bristol-Myers Squibb
- 01 Aug 2022 Results assessing retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe rheumatoid arthritis, published in the Clinical Rheumatology.
- 04 Jun 2022 Results of post-hoc analysis of two studies ((ACTION & ASCORE) assessing independent effect of ACPA or RF single seropositivity among patients with RA on achieving remission after treatment with abatacept for 2 years, and to compare outcomes among patients with single versus double serostatus, presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 04 Jun 2022 Results of post-hoc analysis of two studies (ACTION & ASCORE) assessing the independent effect of ACPA or RF single seropositivity on abatacept retention in patients with rheumatoid arthritis receiving abatacept, presented at the 23rd Annual Congress of the European League Against Rheumatism.